N/A (Healthy adults)
Conditions
Interventions
Oral intake of the test food (yogurt, 112 g) once daily for 8 weeks.
Oral intake of the placebo food (acidified milk, 112 g) once daily for 8 weeks.
Sponsors
CPCC Company Limited
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Healthy Japanese male and female aged 20-64 years at the time of consent acquisition. 2) Subjects who consider themselves prone to catching colds. 3) Subjects who provide written informed consent.
Exclusion criteria
Exclusion criteria: 1) Subjects who have/had serious diseases affecting this study. 2) Subjects with chronic diseases who use medication regularly. 3) Subjects regularly consuming yogurt, lactic acid bacteria beverages, health foods, or supplements for 1 month or more before the screening test. 4) Subjects unable to refrain from consuming yogurt, lactic acid bacteria beverages, health foods, or supplements after consent. 5) Subjects with an average daily alcohol intake exceeding 40 g. 6) Subjects unable to abstain from alcohol for 1 day before the examination. 7) Subjects with smoking habits. 8) Subjects with a history of hay fever between January and April in the past 3 years or potential for hay fever during this study. 9) Subjects with gastrointestinal diseases or past gastrointestinal surgeries affecting digestion/absorption (excluding appendicitis). 10) Subjects with persistent oral problems involving bleeding. 11) Subjects planning to receive any vaccinations from 1 month before the screening test to the 12-week examination. 12) Subjects participating in other research within 4 weeks before consent or planning to participate in other research after consent. 13) Subjects who are engaged in day/night shift work. 14) Subjects who are pregnant, breastfeeding, or intend to become pregnant during this study. 15) Subjects prone to diarrhea after consuming dairy. 16) Subjects with milk allergies. 17) Subjects who donated component blood or 200 mL whole blood within 1 month before this study. 18) Males who donated 400 mL of whole blood within 3 months before this study. 19) Females who donated 400 mL of whole blood within 4 months before this study. 20) Males whose total blood draw volume, including the planned volume for this study, exceeds 1,200 mL within 12 months before this study. 21) Females whose total blood draw volume, including the planned volume for this study, exceeds 800 mL within 12 months before this study. 22) Subjects deemed unsuitable by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The concentration and secretion rate of salivary s-IgA | — |
Secondary
| Measure | Time frame |
|---|---|
| Salivary secretion rate, cold-like symptoms, dendritic cell activity, cytokine production in PBMC, and NK cell activity | — |
Countries
Japan
Contacts
Public ContactMakoto Ichinohe
CPCC Company Limited Clinical Planning Department
Outcome results
None listed